ERBB2 and breast cancer: Assess the tumor response rate to trastuzumab‐emtansine in patients with metastatic HER2‐negative BC but HER2‐amplified CTCs (at least one HER2‐amplified CTC/7.5ml, as determined by CellSearch® and FISH) who had received at least two lines of chemotherapy